Drugs / BCD-281
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07321093 | Nov 2025 → Dec 2028 expected | relapsing-remitting multiple sclerosis | Biocad | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCD-281 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07321093 ↗ |
| Modality | Monoclonal antibody | “anti-CD20 monoclonal antibody” NCT07321093 ↗ |